Similar articles for PMID: 24492289

Year	Number of Results
1995	2
2000	1
2003	1
2005	2
2007	4
2008	5
2009	5
2010	7
2011	11
2012	13
2013	20
2014	35
2015	18
2016	5
2017	10
2018	13
2019	3
2020	8
2021	31
2022	33
2023	10
2024	0

1

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.

Kang JC, Poovassery JS, Bansal P, You S, Manjarres IM, Ober RJ, Ward ES. Kang JC, et al. MAbs. 2014 Mar-Apr;6(2):340-53. doi: 10.4161/mabs.27658. Epub 2013 Dec 26. MAbs. 2014. PMID: 24492289 Free PMC article.

2

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL. Xia W, et al. Breast Cancer Res. 2013;15(5):R85. doi: 10.1186/bcr3480. Breast Cancer Res. 2013. PMID: 24044505 Free PMC article.

3

Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.

Poovassery JS, Kang JC, Kim D, Ober RJ, Ward ES. Poovassery JS, et al. Int J Cancer. 2015 Jul 15;137(2):267-77. doi: 10.1002/ijc.29378. Epub 2014 Dec 19. Int J Cancer. 2015. PMID: 25471734 Free article.

4

Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.

Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL. Garrett JT, et al. Cancer Res. 2013 Oct 1;73(19):6013-23. doi: 10.1158/0008-5472.CAN-13-1191. Epub 2013 Aug 5. Cancer Res. 2013. PMID: 23918797 Free PMC article.

5

An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.

Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA. Garner AP, et al. Cancer Res. 2013 Oct 1;73(19):6024-35. doi: 10.1158/0008-5472.CAN-13-1198. Epub 2013 Aug 8. Cancer Res. 2013. PMID: 23928993 Free PMC article.

6

Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.

Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K. Watanabe S, et al. Cancer Med. 2019 Mar;8(3):1258-1268. doi: 10.1002/cam4.1995. Epub 2019 Jan 31. Cancer Med. 2019. PMID: 30701699 Free PMC article.

7

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J. Anido J, et al. Clin Cancer Res. 2003 Apr;9(4):1274-83. Clin Cancer Res. 2003. PMID: 12684395

8

Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.

Razumienko EJ, Scollard DA, Reilly RM. Razumienko EJ, et al. J Nucl Med. 2012 Dec;53(12):1943-50. doi: 10.2967/jnumed.112.106906. Epub 2012 Oct 24. J Nucl Med. 2012. PMID: 23096164 Free article.

9

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.

Leto SM, Sassi F, Catalano I, Torri V, Migliardi G, Zanella ER, Throsby M, Bertotti A, Trusolino L. Leto SM, et al. Clin Cancer Res. 2015 Dec 15;21(24):5519-31. doi: 10.1158/1078-0432.CCR-14-3066. Epub 2015 Aug 21. Clin Cancer Res. 2015. PMID: 26296355

10

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.

Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Garrett JT, et al. Clin Cancer Res. 2013 Feb 1;19(3):610-9. doi: 10.1158/1078-0432.CCR-12-2024. Epub 2012 Dec 5. Clin Cancer Res. 2013. PMID: 23224399 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

202 results

Results by year